Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

86.75 +0.47 (+0.54%)
Official Closing Price Updated: 4:10 PM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,318,578
Open 86.69
Bid (Size) 86.40 (100)
Ask (Size) 86.75 (400)
Prev. Close 86.28
Today's Range 85.80 - 87.37
52wk Range 73.31 - 105.07
Shares Outstanding 2,531,374,696
Dividend Yield 3.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cliff Asness: The Stock Market is Expensive, Not a Bubble – A Call for Rationality in a Less Efficient Market
New York, NY – November 10, 2025 – In a financial landscape often characterized by extremes, Cliff Asness, the influential co-founder of AQR Capital Management, offers a nuanced yet stark assessment of... 
Via MarketMinute
Topics Economy
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
-12.5%
-12.5%
1 Month
+0.9%
+0.9%
3 Month
+8.4%
+8.4%
6 Month
+7.9%
+7.9%
1 Year
-13.9%
-13.9%

More News

Read More
Merck Stock Rises Upon Receipt Of $700M In Funding For Experimental Cancer Drug
Via Stocktwits
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%
Via Investor's Business Daily
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
From Merck & Co., Inc.
Via Business Wire
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Herkimer College Pioneers New AI-Business Degree to Forge Future-Ready Workforce
Via TokenRing AI
Topics Artificial Intelligence Economy Fraud
3 Dirt Cheap Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
2 Safe-and-Steady Stocks Worth Your Attention and 1 We Turn Down
Via StockStory
ESG Investing's Future: Navigating Regulatory Currents and Sustainable Fund Performance
Via MarketMinute
Topics Artificial Intelligence Bonds Climate Change
Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Case for Dividend Investors
Via Chartmill
3 Reasons Investors Love Merck (MRK)
Via StockStory
Topics Stocks Supply Chain
MarketMinute: The Rise of Precision Swine Farming – A New Frontier in Agri-Tech Investment
Via MarketMinute
Topics Artificial Intelligence Supply Chain
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
Via MarketMinute
Topics Economy
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence
Why Merck Is Sinking This Week
Via The Motley Fool
Topics Intellectual Property
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
From Merck & Co., Inc.
Via Business Wire
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
From Merck & Co., Inc.
Via Business Wire
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Energy Stocks
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
From Merck Sharp & Dohme
Via Business Wire
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Via MarketMinute
Topics Intellectual Property

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 86.75
When was Merck & Co last traded?
The last trade of Merck & Co was at 11/10/25 04:10 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 219.60B
How many shares of Merck & Co are outstanding?
Merck & Co has 220B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.